Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining clinically relevant molecular subsets of lung cancer.

Cancer chemotherapy and pharmacology - 1 Nov 2006

Pao William

Abstract excerpt

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, induce dramatic responses in certain patients with non-small cell lung cancer (NSCLC). As such, the drugs provide an unexpected tool to dissect clinically relevant molecular subsets of NSCLC. For example, using mutational profiling of tumor DNA from patients with sensitivity, primary resistance, and secondary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, ras

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 17093937
DOI: 10.1007/s00280-006-0310-x

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining clinically relevant molecular subsets of lung cancer.PMID 17093937Read ↗

EGFR mutant lung cancer.Semantic proximity Read ↗

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.Semantic proximity Read ↗

Molecular pathology of lung cancer: key to personalized medicine.Semantic proximity Read ↗

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.Semantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in lung adenocarcinoma.Semantic proximity Read ↗

The evolving genomic classification of lung cancer.Semantic proximity Read ↗

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).Semantic proximity Read ↗

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.